DDrare: Database of Drug Development for Rare Diseases

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-000385-55-FR (EUCTR)	12/05/2015	29/03/2017	Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.	TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO	Rendu-Osler disease MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Timolol Alcon 0.5% collyre Other descriptive name: TIMOLOL MALEATE	Hospices Civils de Lyon	NULL	Not Recruiting			Female: yes Male: yes	58	Phase 2	France
2	NCT01752049 (ClinicalTrials.gov)	May 2013	14/12/2012	Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept	Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept	Hereditary Hemorrhagic Telangiectasia	Drug: Topical timolol maleate;Drug: placebo saline drops	St. Michael's Hospital, Toronto	University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)	Completed	18 Years	N/A	All	5	N/A	Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2015-000385-55-FR
(EUCTR)

12/05/2015

29/03/2017

Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.

TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO

Rendu-Osler disease
MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Timolol Alcon 0.5% collyre
Other descriptive name: TIMOLOL MALEATE

Hospices Civils de Lyon

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France

NCT01752049
(ClinicalTrials.gov)

May 2013

14/12/2012

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Hereditary Hemorrhagic Telangiectasia

Drug: Topical timolol maleate;Drug: placebo saline drops

St. Michael's Hospital, Toronto

University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)

Completed

18 Years

N/A

All

N/A

Canada